Guardant Health, Inc. Common Stock
GH Real Time Price USDRecent trades of GH by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in GH holdings by institutional investors
Quarterly net insider trading by GH's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$180,000 Jul 20, 2026 Issue: Medicare/Medicaid Health Issues
-
$241,000 Apr 20, 2026 Issue: Medicare/Medicaid Health Issues
-
$741,000 Jan 20, 2026 Issue: Medicare/Medicaid Health Issues
-
$241,000 Oct 17, 2025 Issue: Medicare/Medicaid Health Issues
-
$241,000 Jul 27, 2025 Issue: Medicare/Medicaid Health Issues
-
$241,000 Apr 21, 2025 Issue: Medicare/Medicaid Health Issues
-
$260,000 Jan 08, 2025 Issue: Medicare/Medicaid Health Issues
-
$260,000 Oct 20, 2024 Issue: Health Issues Medicare/Medicaid
-
$260,000 Aug 12, 2024 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jul 15, 2024 Issue: Budget/Appropriations Health Issues
-
$260,000 Jan 19, 2024 Issue: Health Issues Medicare/Medicaid
-
$260,000 Oct 19, 2023 Issue: Health Issues Medicare/Medicaid
-
$260,000 Jul 20, 2023 Issue: Health Issues Medicare/Medicaid
-
$220,000 Jan 19, 2023 Issue: Veterans Labor Issues/Antitrust/Workplace Health Issues Medicare/Medicaid
-
$220,000 Oct 20, 2022 Issue: Veterans Labor Issues/Antitrust/Workplace Health Issues Medicare/Medicaid
-
$220,000 Jul 20, 2022 Issue: Labor Issues/Antitrust/Workplace Health Issues Medicare/Medicaid
-
$220,000 Apr 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$200,000 Jan 21, 2022 Issue: None
-
$200,000 Oct 19, 2021 Issue: None
-
$200,000 Jul 20, 2021 Issue: None
-
$200,000 Apr 21, 2021 Issue: None
-
$160,000 Jan 20, 2021 Issue: None
-
$160,000 Oct 20, 2020 Issue: None
-
$180,000 Jul 20, 2020 Issue: None
-
$167,500 Apr 20, 2020 Issue: None
-
$70,000 Jan 20, 2020 Issue: None
-
$70,000 Oct 20, 2019 Issue: Medicare/Medicaid Health Issues
-
$60,000 Jul 22, 2019 Issue: Veterans Health Issues Medicare/Medicaid
-
$60,000 Apr 17, 2019 Issue: Veterans Health Issues
-
$60,000 Jan 18, 2019 Issue: Budget/Appropriations Health Issues Veterans
-
$60,000 Oct 18, 2018 Issue: Health Issues
-
$60,000 Jul 20, 2018 Issue: Health Issues
-
$60,000 Apr 20, 2018 Issue: Health Issues Medicare/Medicaid
-
$60,000 Jan 22, 2018 Issue: Health Issues Medicare/Medicaid
-
$60,000 Oct 20, 2017 Issue: Health Issues Medicare/Medicaid
-
$60,000 Jul 19, 2017 Issue: Health Issues Medicare/Medicaid
-
$60,000 Apr 20, 2017 Issue: Health Issues Medicare/Medicaid
-
$20,000 Jan 18, 2017 Issue: Health Issues
Former government officials who have lobbied for GH
27 former government officials from 18 congressional offices at 7 lobbying firms have lobbied for GH, most recently Jul 21, 2026.
-
Paul Edattel House Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg -
Daniel Todd Senate Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
-
Nicholas Uehlecke House Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
-
Jennifer Leib Senate Fellow, Senate Committee on Health, Education, Labor, and Pensions
-
Nicholas Bath Senate Health Policy Director of the U.S. Senate Committee on Health, Education, Labor and Pensions
-
Edward Waters House Legislative Assistant to Rep. Timothy Bishop (NY-01) -
Christopher Gillott Senate New Sen. Bill Cassidy: Deputy Chief of Staff, Policy (2018-2021); Legislative Dir (2013-2021); Sr Legislative Asst (2013); Rep. Bobby Jindal: Leg. Dir (2007-2008); Sr Legislative Asst (2005-2007); Sen. Kay Bailey Hutchison: Leg Aide (2003-2005) -
Stephen Weyler House New Health and Labor Fellow, U.S. House of Representatives, Committee on Education & Labor (2019)
GH Estimated quarterly lobbying spending
GH Revenue by Segment or Geography
New GH patent grants
-
Patent Title: Predictive model for determining changes in molecular state Sep. 22, 2026
-
Patent Title: Sequencing methods with partitioning Sep. 22, 2026
-
Patent Title: Systems and methods to detect rare mutations and copy number variation Sep. 15, 2026
-
Patent Title: Microsatellite instability detection in cell-free dna Aug. 25, 2026
-
Patent Title: Microsatellite instability detection in cell-free dna Aug. 25, 2026
-
Patent Title: Population based treatment recommender using cell free dna Aug. 11, 2026
-
Patent Title: Population based treatment recommender using cell free dna Aug. 11, 2026
-
Patent Title: Identification of somatic or germline origin for cell-free dna Aug. 04, 2026
-
Patent Title: Systems and methods to detect rare mutations and copy number variation Jul. 28, 2026
-
Patent Title: Microsatellite instability detection in cell-free dna Jul. 28, 2026
-
Patent Title: Computational modeling of loss of function based on allelic frequency Jun. 23, 2026
-
Patent Title: Systems and methods to detect rare mutations and copy number variation Jun. 23, 2026
-
Patent Title: Compositions and methods for analyzing cell-free dna in methylation partitioning assays Jun. 16, 2026
-
Patent Title: Compositions and methods for isolating cell-free dna May. 19, 2026
-
Patent Title: Systems and methods to detect rare mutations and copy number variation May. 12, 2026
-
Patent Title: Systems and methods to detect rare mutations and copy number variation Apr. 21, 2026
-
Patent Title: Methods and applications of gene fusion detection in cell-free dna analysis Apr. 14, 2026
-
Patent Title: Cancer evolution detection and diagnostic Apr. 07, 2026
-
Patent Title: Methods for fragmentome profiling of cell-free nucleic acids Mar. 31, 2026
-
Patent Title: Methods for early detection of cancer Mar. 10, 2026
-
Patent Title: Methods for early detection of cancer Mar. 10, 2026
-
Patent Title: Genetic variant detection based on merged and unmerged reads Mar. 03, 2026
-
Patent Title: Methods and systems for analyzing nucleic acid molecules Mar. 03, 2026
-
Patent Title: Computer architecture for identifying lines of therapy Feb. 10, 2026
-
Patent Title: Methods and systems for analyzing nucleic acid molecules Feb. 10, 2026
-
Patent Title: Network bandwidth architecture for bioinformatics system Dec. 16, 2025
-
Patent Title: Computer architecture for generating an integrated data repository Nov. 18, 2025
-
Patent Title: Sequencing methods with partitioning Nov. 11, 2025
-
Patent Title: Data processing abstraction for high performance computing systems Oct. 28, 2025
-
Patent Title: Single namespace for high performance computing system Oct. 28, 2025
-
Patent Title: Methods and systems for detecting genetic variants Oct. 07, 2025
-
Patent Title: Methods and systems for analyzing nucleic acid molecules Sep. 30, 2025
-
Patent Title: Normalizing tumor mutation burden Aug. 12, 2025
-
Patent Title: Methods and systems for analyzing nucleic acid molecules Jul. 15, 2025
-
Patent Title: Microsatellite instability detection in cell-free dna Jul. 01, 2025
-
Patent Title: Methods for multi-resolution analysis of cell-free nucleic acids Jun. 24, 2025
-
Patent Title: Display screen or portion thereof with graphical user interface Jun. 03, 2025
-
Patent Title: Methods for detecting and suppressing alignment errors caused by fusion events Jun. 03, 2025
-
Patent Title: Gene mutations and copy number alterations of egfr, kras and met Jun. 03, 2025
-
Patent Title: Methods and systems for detecting genetic variants Jun. 03, 2025
-
Patent Title: Methods and systems for analyzing nucleic acid molecules May. 27, 2025
-
Patent Title: Method for the detection of cancer Jun. 06, 2023
-
Patent Title: Methods and systems for detecting genetic variants Mar. 20, 2018
-
Patent Title: Systems and methods to detect rare mutations and copy number variation Feb. 27, 2018
-
Patent Title: Methods for multi-resolution analysis of cell-free nucleic acids Dec. 26, 2017
-
Patent Title: Systems and methods to detect rare mutations and copy number variation Dec. 12, 2017
-
Patent Title: Systems and methods to detect rare mutations and copy number variation Dec. 05, 2017
-
Patent Title: Systems and methods to detect rare mutations and copy number variation Oct. 17, 2017
-
Patent Title: Systems and methods to detect rare mutations and copy number variation Mar. 21, 2017
-
Patent Title: Method for the detection of cancer Nov. 12, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded to GH from public contracts
Recent insights relating to GH
Recent picks made for GH stock on CNBC
ETFs with the largest estimated holdings in GH
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $GH stock a Buy, Sell, or Hold?
- What is the price target for $GH stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $GH stock?
- Who owns the most shares of $GH stock?
- What funds own $GH stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GH Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
- Address Palo Alto, CA
- Market Cap 23.9 billion
- Employees 2,506
- Industrial Classification Services-Medical Laboratories
Guardant Health, Inc. Common Stock (GH) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Guardant Health, Inc. Common Stock (GH).
Quiver Premium charts GH's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at GH, per a recent SEC DEF 14A filing. We estimate that the median employee at Guardant Health, Inc. is paid $215,141.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|